Roche Looks to Push Gazyva Into Lupus Nephritis With Promising Late-Stage Data

In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis versus placebo, positioning Roche’s therapeutic antibody for expansion into the indication.